These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 16858202)

  • 1. Prevention of intra-abdominal adhesions using the antiangiogenic COX-2 inhibitor celecoxib.
    Cahill RA
    Ann Surg; 2006 Aug; 244(2):327-8; author reply 328. PubMed ID: 16858202
    [No Abstract]   [Full Text] [Related]  

  • 2. Prevention of intra-abdominal adhesions using the antiangiogenic COX-2 inhibitor celecoxib.
    Greene AK; Alwayn IP; Nose V; Flynn E; Sampson D; Zurakowski D; Folkman J; Puder M
    Ann Surg; 2005 Jul; 242(1):140-6. PubMed ID: 15973112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective inhibition of cyclooxygenase-2 suppresses metastatic disease without affecting primary tumor growth in a murine model of Ewing sarcoma.
    Gendy AS; Lipskar A; Glick RD; Steinberg BM; Edelman M; Soffer SZ
    J Pediatr Surg; 2011 Jan; 46(1):108-14. PubMed ID: 21238650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective cyclooxygenase-2 inhibition with celecoxib decreases angiotensin II-induced abdominal aortic aneurysm formation in mice.
    King VL; Trivedi DB; Gitlin JM; Loftin CD
    Arterioscler Thromb Vasc Biol; 2006 May; 26(5):1137-43. PubMed ID: 16514081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The select cyclooxygenase-2 inhibitor celecoxib reduced the extent of atherosclerosis in apo E-/- mice.
    Jacob S; Laury-Kleintop L; Lanza-Jacoby S
    J Surg Res; 2008 May; 146(1):135-42. PubMed ID: 17950326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancement of glioblastoma radioresponse by a selective COX-2 inhibitor celecoxib: inhibition of tumor angiogenesis with extensive tumor necrosis.
    Kang KB; Wang TT; Woon CT; Cheah ES; Moore XL; Zhu C; Wong MC
    Int J Radiat Oncol Biol Phys; 2007 Mar; 67(3):888-96. PubMed ID: 17293239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Prophylactic effect of a selective COX-2 inhibitor celecoxib on carcinogen-induced gastric premalignant lesions in rats].
    Tang BD; Zeng ZR; Hu PJ
    Ai Zheng; 2006 Oct; 25(10):1205-9. PubMed ID: 17059761
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemopreventive effect of celecoxib in gastric cancer.
    Futagami S; Suzuki K; Hiratsuka T; Shindo T; Hamamoto T; Ueki N; Kusunoki M; Miyake K; Gudis K; Tsukui T; Sakamoto C
    Inflammopharmacology; 2007 Feb; 15(1):1-4. PubMed ID: 17323186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Celecoxib may decrease some skin cancers.
    Nurse Pract; 2010 Jun; 35(6):17. PubMed ID: 20479622
    [No Abstract]   [Full Text] [Related]  

  • 10. Celecoxib for lupus.
    Wallace DJ
    Arthritis Rheum; 2008 Sep; 58(9):2923. PubMed ID: 18759281
    [No Abstract]   [Full Text] [Related]  

  • 11. Dopaminergic but not glutamatergic neurotransmission is increased in the striatum after selective cyclooxygenase-2 inhibition in normal and hemiparkinsonian rats.
    Moghaddamt HF; Ardestani MS; Saffari M; Navidpour L; Shafiee A; Rahmim A
    Basic Clin Pharmacol Toxicol; 2008 Oct; 103(4):293-6. PubMed ID: 18764909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apoptosis of murine lupus T cells induced by the selective cyclooxygenase-2 inhibitor celecoxib: molecular mechanisms and therapeutic potential.
    Yang P; Zhang Y; Ping L; Gao XM
    Int Immunopharmacol; 2007 Nov; 7(11):1414-21. PubMed ID: 17761345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cyclooxygenase-2 inhibitor celecoxib and alveolar osteitis (Journal of the Irish Dental Association 2011; 57 (1): 50-53).
    Hackett JF
    J Ir Dent Assoc; 2011; 57(3):127. PubMed ID: 21834146
    [No Abstract]   [Full Text] [Related]  

  • 14. COX-2 in cardiovascular disease.
    Bishop-Bailey D; Mitchell JA; Warner TD
    Arterioscler Thromb Vasc Biol; 2006 May; 26(5):956-8. PubMed ID: 16627818
    [No Abstract]   [Full Text] [Related]  

  • 15. The immune tolerance of cancer is mediated by IDO that is inhibited by COX-2 inhibitors through regulatory T cells.
    Lee SY; Choi HK; Lee KJ; Jung JY; Hur GY; Jung KH; Kim JH; Shin C; Shim JJ; In KH; Kang KH; Yoo SH
    J Immunother; 2009 Jan; 32(1):22-8. PubMed ID: 19307990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The anti-proliferative potency of celecoxib is not a class effect of coxibs.
    Schiffmann S; Maier TJ; Wobst I; Janssen A; Corban-Wilhelm H; Angioni C; Geisslinger G; Grösch S
    Biochem Pharmacol; 2008 Jul; 76(2):179-87. PubMed ID: 18547544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pilot randomized phase II study of celecoxib in oral premalignant lesions.
    Papadimitrakopoulou VA; William WN; Dannenberg AJ; Lippman SM; Lee JJ; Ondrey FG; Peterson DE; Feng L; Atwell A; El-Naggar AK; Nathan CO; Helman JI; Du B; Yueh B; Boyle JO
    Clin Cancer Res; 2008 Apr; 14(7):2095-101. PubMed ID: 18381950
    [TBL] [Abstract][Full Text] [Related]  

  • 18. COX-2 inhibitor, celecoxib, may prevent lung cancer.
    Oncology (Williston Park); 2011 Aug; 25(9):848-9. PubMed ID: 21936449
    [No Abstract]   [Full Text] [Related]  

  • 19. Cyclooxygenase-2 inhibitor: a potential therapeutic strategy for ultrafiltration failure in peritoneal dialysis.
    Kim YL; Park SH; Choi JY; Kim CD
    Nephrol Dial Transplant; 2009 Dec; 24(12):3585-8. PubMed ID: 19783596
    [No Abstract]   [Full Text] [Related]  

  • 20. Chronic pretreatment with celecoxib reduces infarct size.
    Lada-Moldovan L; Kaloustian S; Bah TM; Girard SA; Déry MA; Rousseau G
    J Cardiovasc Pharmacol; 2009 Jul; 54(1):31-7. PubMed ID: 19528817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.